The SUMMIT trial investigated tirzepatide, a dual GIP and GLP-1 receptor agonist, in 731 patients with HFpEF and obesity.
This randomized, placebo-controlled study found that tirzepatide reduced heart failure-related events (HR 0.62, P=0.026) and significantly improved quality of life (KCCQ-CSS +19.5 vs. +12.7, P<0.001).
However, cardiovascular mortality was not significantly different.
Gastrointestinal side effects led to a 6.3% discontinuation rate.
The findings suggest a potential role for metabolic intervention in HFpEF, but long-term safety and broader applicability require further research.
